Featured Research

from universities, journals, and other organizations

Breast Cancer Subtypes Linked To Survival From Secondary Brain Tumors

Date:
March 1, 2008
Source:
BioMed Central/Breast Cancer Research
Summary:
Screening breast cancers for three receptors could help doctors predict the likely survival of patients with brain metastases. A new study shows that patients with tumours that are negative for estrogen receptor, progesterone receptor and human epidermal growth receptor-2 or that are HER2+/ER- appear to be most at risk from developing brain metastases. Survival is also correlated to the triple receptor status.

Screening breast cancers for three receptors could help doctors predict the likely survival of patients with brain metastases. A study published in the open access journal Breast Cancer Research shows that patients with tumours that are negative for estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth receptor-2 (HER2) or that are HER2+/ER- appear to be most at risk from developing brain metastases. Survival is also correlated to the triple receptor status.

This is the first time that researchers have documented a possible link between breast cancer subtypes and the incidence and prognosis of brain metastases, which occur in up to one third of metastatic breast cancer patients.

A team from the National Cancer Centre in the Republic of Korea analysed data from 126 patients with brain metastases from a pool of 805 patients diagnosed with metastatic breast cancer and treated at the Centre. The presence or absence of ER, PR and HER2 were tested by immunohistochemical staining and/or fluorescent in situ hybridisation.

More than half of the patients with early (non-metastatic) breast cancer were of the luminal A subtype (ER or PR+ and HER2-). The proportion of patients with HER2+/ER- or triple-negative tumours was significantly higher among patients with brain metastases compared to the early breast cancer population, suggesting that these latter two subtypes were associated with the development of brain metastases.

The analysis also showed a correlation between the survival of patients and their triple receptor subtypes following the diagnosis of brain metastases, the survival time of which is just 3 -- 6 months. Patients with luminal A (4.0 months) and triple-negative tumours (3.4 months) had a similar shorter survival time compared with luminal B (ER or PR+ and HER2+; 9.2 months) and HER2+/ER- (5.0 months) tumours.

Patients with HER2-positive tumours experienced a significant survival benefit if they were treated with trastuzumab after their brain metastases were diagnosed.

"Our study suggests that the triple-negative subtype should be added to the list of risk factors for developing BM," remarks Jungsil Ro, the study's corresponding author. "Approximately 10-15% of all breast cancer presents this phenotype; they have a poor prognosis and are more likely to develop brain metastases. Triple receptor status can also help to predict survival even after brain metastases have been diagnosed. We now need to develop ways to screen for these subtypes and find the best ways to manage patients with this more aggressive phenotype."

Journal reference: Breast cancer subtypes and survival in patients with brain metastases. Byung-Ho Nam, Sun Young Kim, Hye-Suk Han, Youngmee Kwon, Keun Seok Lee, Tae Hyun Kim and Jungsil Ro. Breast Cancer Research (in press).


Story Source:

The above story is based on materials provided by BioMed Central/Breast Cancer Research. Note: Materials may be edited for content and length.


Cite This Page:

BioMed Central/Breast Cancer Research. "Breast Cancer Subtypes Linked To Survival From Secondary Brain Tumors." ScienceDaily. ScienceDaily, 1 March 2008. <www.sciencedaily.com/releases/2008/02/080227205118.htm>.
BioMed Central/Breast Cancer Research. (2008, March 1). Breast Cancer Subtypes Linked To Survival From Secondary Brain Tumors. ScienceDaily. Retrieved September 20, 2014 from www.sciencedaily.com/releases/2008/02/080227205118.htm
BioMed Central/Breast Cancer Research. "Breast Cancer Subtypes Linked To Survival From Secondary Brain Tumors." ScienceDaily. www.sciencedaily.com/releases/2008/02/080227205118.htm (accessed September 20, 2014).

Share This



More Health & Medicine News

Saturday, September 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Sierra Leone's Nationwide Ebola Curfew Underway

Sierra Leone's Nationwide Ebola Curfew Underway

Newsy (Sep. 20, 2014) Sierra Leone is locked down as aid workers and volunteers look for new cases of Ebola. Video provided by Newsy
Powered by NewsLook.com
Changes Found In Brain After One Dose Of Antidepressants

Changes Found In Brain After One Dose Of Antidepressants

Newsy (Sep. 19, 2014) A study suggest antidepressants can kick in much sooner than previously thought. Video provided by Newsy
Powered by NewsLook.com
Could Grief Affect The Immune Systems Of Senior Citizens?

Could Grief Affect The Immune Systems Of Senior Citizens?

Newsy (Sep. 19, 2014) The study found elderly people are much more likely to become susceptible to infection than younger adults going though a similar situation. Video provided by Newsy
Powered by NewsLook.com
Jury Delivers Verdict in Salmonella Trial

Jury Delivers Verdict in Salmonella Trial

AP (Sep. 19, 2014) A federal jury has convicted three people in connection with an outbreak of salmonella poisoning five years ago that sickened hundreds of people and was linked to a number of deaths. (Sept. 19) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins